当前位置:首页 - 行情中心 - 南模生物(688265) - 财务分析 - 利润表

南模生物

(688265)

  

流通市值:50.66亿  总市值:50.66亿
流通股本:7796.35万   总股本:7796.35万

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入232,436,961.6899,917,106.36421,024,337.24302,700,815.36
  营业收入232,436,961.6899,917,106.36421,024,337.24302,700,815.36
二、营业总成本229,620,819.95101,847,429.13406,371,770.42285,426,118.09
  营业成本105,730,314.1746,005,201.14203,399,567.65142,671,588.01
  税金及附加1,082,446.35703,486.022,703,374.21,813,578.59
  销售费用39,975,530.916,680,650.3660,519,398.942,999,153.23
  管理费用35,437,508.4416,360,772.1651,017,223.9633,771,016.94
  研发费用44,362,643.820,461,429.886,688,501.8462,717,010.22
  财务费用3,032,376.291,635,889.652,043,703.871,453,771.1
  其中:利息费用1,076,484.85556,554.212,415,789.511,857,809.49
  其中:利息收入1,580,912.56638,286.432,576,854.682,084,904.07
三、其他经营收益
  加:公允价值变动收益7,704,944.583,734,189.8317,682,289.1212,582,196.26
  加:投资收益589,073.61501,606.261,775,193.981,475,730.98
  资产处置收益--38,969.2738,969.27
  资产减值损失(新)-3,837,895.8-2,025,965.64-2,099,198.48-1,604,289.04
  信用减值损失(新)-4,524,298.52-2,337,183.8-10,163,116.15-9,296,325.18
  其他收益5,164,551.522,511,455.78,101,370.696,084,852.09
四、营业利润7,912,517.12453,779.5829,988,075.2526,555,831.65
  加:营业外收入--356.07356.04
  减:营业外支出57,86957,869887,300.77831,398.75
五、利润总额7,854,648.12395,910.5829,101,130.5525,724,788.94
  减:所得税费用-1,221,971.71-287,724.98-2,335,399.21-1,040,116.17
六、净利润9,076,619.83683,635.5631,436,529.7626,764,905.11
(一)按经营持续性分类
  持续经营净利润9,076,619.83683,635.5631,436,529.7626,764,905.11
(二)按所有权归属分类
  归属于母公司股东的净利润9,076,619.83683,635.5631,436,529.7626,764,905.11
  扣除非经常损益后的净利润-3,843,815.99-5,004,375.588,731,594.1710,277,886.16
七、每股收益
  (一)基本每股收益0.120.010.420.34
  (二)稀释每股收益0.120.010.420.34
八、其他综合收益-95,881.7717,200.94-277,676.1-155,144.81
  归属于母公司股东的其他综合收益-95,881.7717,200.94-277,676.1-155,144.81
九、综合收益总额8,980,738.06700,836.531,158,853.6626,609,760.3
  归属于母公司股东的综合收益总额8,980,738.06700,836.531,158,853.6626,609,760.3
公告日期2026-08-292026-04-302026-04-272025-10-30
审计意见(境内)标准无保留意见
TOP↑